Clinical Trial Update: A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II study of Fisogatinib (BLU-554) in hepatocellular carcinoma has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Fisogatinib (BLU-554) (Fisogatinib)

Snippet

Sponsor: CStone Pharmaceuticals | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-06